Skip to main content
Molecular Therapy logoLink to Molecular Therapy
. 2024 Jul 2;32(8):2799. doi: 10.1016/j.ymthe.2024.06.032

lnc-Rps4l-encoded peptide RPS4XL regulates RPS6 phosphorylation and inhibits the proliferation of PASMCs caused by hypoxia

Yiying Li, Junting Zhang, Hanliang Sun, Yujie Chen, Wendi Li, Xiufeng Yu, Xijuan Zhao, Lixin Zhang, Jianfeng Yang, Wei Xin, Yuan Jiang, Guilin Wang, Wenbin Shi, Daling Zhu
PMCID: PMC11405171  PMID: 38959895

Main text

(Molecular Therapy 29, 1421–1424; April 2021)

The following statements intend to disclose the reuse of certain images that the authors left out of the originally published version of the article.

Figures 8A–8E and 8F–8J and Figure S11E were derived from one PH model and shared the same comparison. The comparisons were presented three times to better illustrate the conclusion.

Figures 4C and 4E share the same β-actin blots derived from the same western blot analyses.

Figures 7C and 7E share the same β-actin blots derived from the same western blot analyses.

Figure 6E of this article and Figure 1E of the Molecular Therapy Nucleic Acids article “RPS4XL encoded by lnc-Rps4l inhibits hypoxia-induced pyroptosis by binding HSC70 glycosylation site” (Li et al., 2022, Mol. Ther. Nucleic Acids 28, 920–934, https://doi.org/10.1016/j.omtn.2022.05.033) share the same β-actin blots derived from the same western blot analyses.

The authors apologize for this omission and any confusion it may have caused.


Articles from Molecular Therapy are provided here courtesy of The American Society of Gene & Cell Therapy

RESOURCES